González-López Elena, Mora-Cuesta Víctor M, Roa-Bautista Adriel, Comins-Boo Alejandra, Renaldo André, Irure-Ventura Juan, Iturbe-Fernández David, Tello-Mena Sandra, San Segundo David, Cifrián-Martínez José, López-Hoyos Marcos
Immunology Department, Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain.
Pneumology Department, Marqués de Valdecilla University Hospital, Santander, Spain.
Transplant Direct. 2023 Jun 28;9(7):e1513. doi: 10.1097/TXD.0000000000001513. eCollection 2023 Jul.
Lung transplantation remains the treatment of choice for end-stage lung diseases, and recipient selection is currently based on clinical urgency, ABO compatibility, and donor size. The risk of allosensitization is classically based on HLA mismatch, but eplet mismatch load is increasingly seen to be important in long-term outcomes in solid organ transplantation. Chronic lung allograft dysfunction (CLAD) is relatively common and relevant, affecting almost 50% of patients 5 y after transplantation and being the first cause of death from the first year after transplantation. The overall class-II eplet mismatch load has been associated with CLAD development.
Based on clinical data, 240 lung transplant recipients were eligible for CLAD, and HLA and eplet mismatch was analyzed using the HLAMatchmaker 3.1 software.
A total of 92 (38.3%) lung transplant recipients developed CLAD. The time free-of-CLAD was significantly decreased in patients with presence of DQA1 eplet mismatches ( = 0.015). Furthermore, when other previously described CLAD risk factors were studied in a multivariate analysis, the presence of DQA1 eplet mismatches was found to be independently associated with the early onset of CLAD.
The concept of epitope load has arisen as a new tool to better define donor-recipient immunologic compatibility. The presence of DQA1 eplet mismatches potentially would increase the likelihood of developing CLAD.
肺移植仍然是终末期肺部疾病的首选治疗方法,目前受体选择基于临床紧迫性、ABO血型相容性和供体大小。同种致敏的风险传统上基于HLA错配,但在实体器官移植的长期预后中,表位错配负荷越来越被认为很重要。慢性肺移植功能障碍(CLAD)相对常见且具有相关性,影响近50%的移植后5年患者,并且是移植后第一年死亡的首要原因。总体II类表位错配负荷与CLAD的发生有关。
基于临床数据,240例肺移植受者符合CLAD标准,并使用HLAMatchmaker 3.1软件分析HLA和表位错配情况。
共有92例(38.3%)肺移植受者发生CLAD。存在DQA1表位错配的患者无CLAD的时间显著缩短(P = 0.015)。此外,在多变量分析中研究其他先前描述的CLAD危险因素时,发现存在DQA1表位错配与CLAD的早期发生独立相关。
表位负荷的概念已成为更好地定义供体-受体免疫相容性的新工具。存在DQA1表位错配可能会增加发生CLAD的可能性。